The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Rani Therapeutics Holdings Inc (NASDAQ:RANI) experienced an 18% jump in its stock price following news that the ...

Britons taking GLP-1 weight loss injections could face the unwanted side effect of 'Ozempic face' - a phenomenon causing ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals ...